Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG-SN in Primary Immunodeficiency
NCT01406470Phase 3Completed
- Sponsor
- GC Biopharma
- Start
- Sep 2011
- Primary completion
- Jul 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of IVIg-SN 10% in primary immunodeficiency disease (PID), sponsored by GC Biopharma. Started Sep 2011; status: completed.
02
Drugs
IVIg-SN 10%
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT01406470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01406470.